0000000001261702

AUTHOR

Anne Lise Bienvenu

0000-0003-1502-1851

showing 1 related works from this author

Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19

2020

Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people. In the absence of an approved, recognized effective pre or post-exposure prophylactic drug or vaccine for COVID-19, nor of any approved and validated therapeutic drug, coupled with social and political pressure raised by publicity both regarding the potential beneficial effect of hydroxychloroquine (HCQ) as well as potential risks from HCQ, we urge the immediate proper clinical trials. Specifically, we mean using HCQ for post-exposure of peo…

Drugmedicine.medical_specialtyPost exposureCoronavirus disease 2019 (COVID-19)COVID19media_common.quotation_subject030231 tropical medicineHydroxychloroquine ; COVID-19 ; Chloroquine ; SARS-CoV2 ; antiviral ; malaria ; Systemic lupus erythematosus ; Immunomodulation ; CoronavirusLoading doseImmunomodulation03 medical and health sciencesSystemic lupus erythematosus0302 clinical medicineChloroquineInternal medicineMedicine030212 general & internal medicineCoronavirus malaria antiviralmedia_commonlcsh:R5-920business.industryStandard treatmentPublic Health Environmental and Occupational HealthChloroquineHydroxychloroquineClinical trialEditorialInfectious DiseasesSARS-CoV2lcsh:Medicine (General)businessHydroxychloroquinemedicine.drugOne Health
researchProduct